HK1201858A1 - An improved process for preparation of physiologically active polypeptide complex - Google Patents
An improved process for preparation of physiologically active polypeptide complexInfo
- Publication number
- HK1201858A1 HK1201858A1 HK15102405.8A HK15102405A HK1201858A1 HK 1201858 A1 HK1201858 A1 HK 1201858A1 HK 15102405 A HK15102405 A HK 15102405A HK 1201858 A1 HK1201858 A1 HK 1201858A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- preparation
- physiologically active
- improved process
- active polypeptide
- polypeptide complex
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/10—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using coupling agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20120024136 | 2012-03-08 | ||
PCT/KR2013/001885 WO2013133659A1 (en) | 2012-03-08 | 2013-03-08 | An improved process for preparation of physiologically active polypeptide complex |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1201858A1 true HK1201858A1 (en) | 2015-09-11 |
Family
ID=49117067
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15102405.8A HK1201858A1 (en) | 2012-03-08 | 2015-03-10 | An improved process for preparation of physiologically active polypeptide complex |
Country Status (18)
Country | Link |
---|---|
US (1) | US11168109B2 (ru) |
EP (1) | EP2822972A4 (ru) |
JP (2) | JP6383667B2 (ru) |
KR (1) | KR101679612B1 (ru) |
CN (2) | CN104271604A (ru) |
AR (1) | AR090281A1 (ru) |
AU (1) | AU2013228144B2 (ru) |
CA (1) | CA2866473A1 (ru) |
HK (1) | HK1201858A1 (ru) |
IN (1) | IN2014DN07956A (ru) |
MX (1) | MX369613B (ru) |
MY (1) | MY165211A (ru) |
PH (1) | PH12014502004A1 (ru) |
RU (1) | RU2639256C2 (ru) |
SG (1) | SG11201405537UA (ru) |
TW (2) | TW202033536A (ru) |
UA (1) | UA114192C2 (ru) |
WO (1) | WO2013133659A1 (ru) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR081755A1 (es) * | 2010-04-02 | 2012-10-17 | Hanmi Holdings Co Ltd | Formulacion de accion prolongada de la hormona estimuladora de los foliculos donde se usa un fragmento de inmunoglobulina, metodo de preparacion y metodo para tratar a un sujeto que sufre un trastorno reproductivo |
KR20130049671A (ko) | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
AR090281A1 (es) * | 2012-03-08 | 2014-10-29 | Hanmi Science Co Ltd | Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo |
EA201691795A1 (ru) * | 2014-03-31 | 2017-03-31 | Ханми Фарм. Ко., Лтд. | Способ улучшения растворимости белка и пептида за счет использования связывания с фрагментом fc иммуноглобулина |
CN107708679A (zh) * | 2015-06-04 | 2018-02-16 | 安特里阿比奥有限公司 | 用于制备位点特异性蛋白质偶联物的胺聚乙二醇化方法 |
EP3325496B1 (en) * | 2015-07-24 | 2024-02-07 | Hanmi Pharm. Co., Ltd. | Method of preparing physiologically active polypeptide conjugate |
AU2016321146C1 (en) * | 2015-09-08 | 2021-10-28 | Theripion, Inc. | ApoA-1 fusion polypeptides and related compositions and methods |
KR102231217B1 (ko) * | 2015-09-24 | 2021-03-24 | 한미약품 주식회사 | 면역글로불린 단편의 특정 위치를 연결 부위로 이용한 단백질 결합체 |
KR20190038456A (ko) * | 2017-09-29 | 2019-04-08 | 한미약품 주식회사 | 효력이 향상된 지속성 단백질 결합체 |
CN111978390B (zh) * | 2020-08-31 | 2022-10-14 | 上海景泽生物技术有限公司 | 聚乙二醇修饰的rhBNP及其用途 |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5110906A (en) | 1986-08-21 | 1992-05-05 | The Trustees Of Columbia University In The City Of New York | Derivatives of soluble T-4 |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
US6924264B1 (en) | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
US6756480B2 (en) | 2000-04-27 | 2004-06-29 | Amgen Inc. | Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
WO2002028437A1 (en) | 2000-10-05 | 2002-04-11 | Ares Trading S.A. | Regioselective liquid phase pegylation |
UA81897C2 (ru) | 2000-12-07 | 2008-02-25 | Эли Лилли Энд Компани | Гетерологический пептидилированный глюкагон-1-подобный белок и его применение для изготовления лекарственного средства для лечения пациентов, страдающих ожирением и/или инсулиннезависимым диабетом |
US7312192B2 (en) | 2001-09-07 | 2007-12-25 | Biocon Limited | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
SE526711C2 (sv) | 2003-01-31 | 2005-10-25 | Probi Ab | Nya stammar av Bifidobacterium med förmåga att överleva i magtarmkanalen och producera glutamin in vivo, samt kompositioner och användningar därav |
US20050176108A1 (en) | 2003-03-13 | 2005-08-11 | Young-Min Kim | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
US20040180054A1 (en) | 2003-03-13 | 2004-09-16 | Hanmi Pharm. Co., Ltd. | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
DK2599502T3 (en) | 2003-04-11 | 2017-04-18 | Antriabio Inc | Process for Preparation of Site-Specific Protein Conjugates |
KR101135244B1 (ko) | 2007-11-29 | 2012-04-24 | 한미사이언스 주식회사 | 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물 |
EP1682584B1 (en) | 2003-11-13 | 2013-04-17 | Hanmi Science Co., Ltd. | A pharmaceutical composition comprising an immunoglobulin fc region as a carrier |
US8263084B2 (en) | 2003-11-13 | 2012-09-11 | Hanmi Science Co., Ltd | Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate |
US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
US20080207505A1 (en) | 2005-01-12 | 2008-08-28 | James Kenneth D | Bna Conjugates and Methods of Use |
TWI376234B (en) | 2005-02-01 | 2012-11-11 | Msd Oss Bv | Conjugates of a polypeptide and an oligosaccharide |
KR100754667B1 (ko) | 2005-04-08 | 2007-09-03 | 한미약품 주식회사 | 비펩타이드성 중합체로 개질된 면역글로불린 Fc 단편 및이를 포함하는 약제학적 조성물 |
GB2427360A (en) | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
KR100824505B1 (ko) | 2005-08-16 | 2008-04-22 | 한미약품 주식회사 | 개시 메티오닌 잔기가 제거된 면역글로불린 Fc 영역의대량 생산방법 |
AU2006280587B2 (en) * | 2005-08-16 | 2011-02-24 | Hanmi Science Co., Ltd. | A method for the mass production of immunoglobulin Fc region deleted initial methionine residues |
WO2008051383A2 (en) * | 2006-10-19 | 2008-05-02 | Amgen Inc. | Use of alcohol co-solvents to improve pegylation reaction yields |
JP2008169195A (ja) | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
US7867491B2 (en) | 2007-05-30 | 2011-01-11 | Genexine Co., Ltd. | Immunoglobulin fusion proteins |
JP2009019027A (ja) | 2007-07-16 | 2009-01-29 | Hanmi Pharmaceutical Co Ltd | アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体 |
JPWO2009020094A1 (ja) | 2007-08-09 | 2010-11-04 | 第一三共株式会社 | 疎水性分子で修飾した抗体 |
CA2731546C (en) * | 2008-07-23 | 2013-11-19 | Hanmi Holdings Co., Ltd. | A polypeptide complex comprising non-peptidyl polymer having three functional ends |
CN102256992B (zh) | 2008-12-19 | 2015-04-22 | 印第安纳大学研究及科技有限公司 | 胰岛素类似物 |
RU2495881C2 (ru) | 2009-03-20 | 2013-10-20 | Ханми Холдингс Ко., Лтд. | Способ регулирования условий для сайт-специфического связывания полипептида и непептидильного полимера |
WO2011011073A1 (en) | 2009-07-22 | 2011-01-27 | Ipsen Pharma S.A.S. | Site-specific pegylated or site-specific lipidated igf-1 and analogues of igf-1 |
ES2590679T3 (es) | 2009-07-27 | 2016-11-23 | Lipoxen Technologies Limited | Glicopolisialilación de proteínas diferentes a proteínas de coagulación de la sangre |
WO2011064758A2 (en) | 2009-11-30 | 2011-06-03 | Pfizer Limited | Fusion protein |
RU2012135505A (ru) | 2010-01-19 | 2014-02-27 | Ханми Сайенс Ко., Лтд. | Жидкие составы для конъюгата этитропоэтина длительного действия |
JP5657698B2 (ja) | 2010-01-19 | 2015-01-21 | ハンミ サイエンス カンパニー リミテッドHanmi Scienceco.,Ltd. | 持続型顆粒球コロニー刺激因子結合体の液剤 |
AR080993A1 (es) | 2010-04-02 | 2012-05-30 | Hanmi Holdings Co Ltd | Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina |
AR081755A1 (es) | 2010-04-02 | 2012-10-17 | Hanmi Holdings Co Ltd | Formulacion de accion prolongada de la hormona estimuladora de los foliculos donde se usa un fragmento de inmunoglobulina, metodo de preparacion y metodo para tratar a un sujeto que sufre un trastorno reproductivo |
AR081066A1 (es) | 2010-04-02 | 2012-06-06 | Hanmi Holdings Co Ltd | Conjugado de insulina donde se usa un fragmento de inmunoglobulina |
US9981017B2 (en) | 2010-04-02 | 2018-05-29 | Hanmi Science Co., Ltd. | Insulin conjugate using an immunoglobulin fragment |
KR101330868B1 (ko) | 2010-06-08 | 2013-11-18 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 인슐린 유도체 약물 결합체 |
KR101337797B1 (ko) | 2010-07-14 | 2013-12-06 | 한미사이언스 주식회사 | 지속형 인간 성장 호르몬 결합체 액상 제제 |
KR101382593B1 (ko) * | 2010-07-21 | 2014-04-10 | 한미사이언스 주식회사 | 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물 |
KR101303388B1 (ko) | 2010-10-26 | 2013-09-03 | 한미사이언스 주식회사 | 지속형 인터페론 알파 결합체의 액상 제제 |
KR101830344B1 (ko) | 2010-10-26 | 2018-02-22 | 한미사이언스 주식회사 | 피브로넥틴 단편 및 면역글로불린 단편의 융합 단백질 및 이의 용도 |
CN103502264A (zh) | 2011-04-04 | 2014-01-08 | 国立大学法人东京医科齿科大学 | Hiv立体结构识别抗体诱导肽 |
UA113626C2 (xx) | 2011-06-02 | 2017-02-27 | Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії | |
EP3878859B1 (en) | 2011-06-10 | 2023-11-01 | Hanmi Science Co., Ltd. | Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same |
WO2012173422A1 (en) | 2011-06-17 | 2012-12-20 | Hanmi Science Co., Ltd. | A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof |
JP6284478B2 (ja) | 2011-09-05 | 2018-02-28 | ハンミ サイエンス カンパニー リミテッド | インターフェロンアルファ結合体を含む癌治療用医薬組成物 |
US9597378B2 (en) | 2011-10-06 | 2017-03-21 | Hanmi Science Co., Ltd. | Blood coagulation factor VII and VIIa derivatives, conjugates and complexes comprising the same, and use thereof |
KR20130049671A (ko) | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
KR101895047B1 (ko) | 2011-12-30 | 2018-09-06 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체 |
AU2013216943B2 (en) | 2012-02-10 | 2018-04-19 | Research Corporation Technologies, Inc. | Fusion proteins comprising immunoglobulin constant domain-derived scaffolds |
AR090281A1 (es) * | 2012-03-08 | 2014-10-29 | Hanmi Science Co Ltd | Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo |
US10064951B2 (en) | 2012-03-30 | 2018-09-04 | Hanmi Science Co., Ltd. | Liquid formulation of highly concentrated long-acting human growth hormone conjugate |
CN103509118B (zh) | 2012-06-15 | 2016-03-23 | 郭怀祖 | 胰岛素-Fc融合蛋白 |
BR112015001052B8 (pt) | 2012-07-19 | 2022-12-27 | Oxford Nanopore Tech Ltd | Métodos para distinguir um polinucleotídeo alvo,sensor para distinguir um polinucleotídeo alvo, e, uso de um construto |
KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
AR091902A1 (es) | 2012-07-25 | 2015-03-11 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de un conjugado de insulina de accion prolongada |
AR094821A1 (es) | 2012-07-25 | 2015-09-02 | Hanmi Pharm Ind Co Ltd | Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada |
AR092862A1 (es) | 2012-07-25 | 2015-05-06 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion |
US10441665B2 (en) | 2012-07-25 | 2019-10-15 | Hanmi Pharm. Co., Ltd. | Liquid formulation of long acting insulinotropic peptide conjugate |
KR101993393B1 (ko) | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
EA031852B1 (ru) | 2012-11-06 | 2019-03-29 | Ханми Фарм. Ко., Лтд. | Жидкая композиция белкового конъюгата, содержащего оксинтомодулин и фрагмент иммуноглобулина |
PT2963056T (pt) * | 2013-02-26 | 2020-02-19 | Hanmi Pharm Ind Co Ltd | Análogo de insulina e utilização do mesmo |
US10046061B2 (en) * | 2013-02-26 | 2018-08-14 | Hanmi Pharm. Co., Ltd | Site-specific insulin conjugate |
BR112015021764B1 (pt) * | 2013-03-05 | 2022-07-19 | Hanmi Pharm. Co., Ltd. | Método de preparação melhorado para a produção com alto rendimento de conjugado de polipeptídeo fisiologicamente ativo |
AR096890A1 (es) | 2013-07-12 | 2016-02-03 | Hanmi Pharm Ind Co Ltd | Conjugando fc de inmunoglobulina, que mantiene la afinidad de unión del fragmento fc de la inmunoglobulina a fcrn |
AR096891A1 (es) | 2013-07-12 | 2016-02-03 | Hanmi Pharm Ind Co Ltd | Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo |
CA2925416A1 (en) | 2013-09-27 | 2015-04-02 | Hanmi Pharm. Co., Ltd. | Sustained type human growth hormone preparation |
TWI684458B (zh) | 2014-05-30 | 2020-02-11 | 南韓商韓美藥品股份有限公司 | 包含胰島素及glp-1/昇糖素雙重促效劑之治療糖尿病之組成物 |
KR20150140177A (ko) | 2014-06-05 | 2015-12-15 | 한미약품 주식회사 | 단백질 및 펩타이드의 면역원성을 감소시키는 방법 |
AU2016382394B2 (en) | 2015-12-31 | 2019-07-04 | Hanmi Pharm. Co., Ltd. | Long-acting conjugate of triple glucagon/GLP-1/GIP receptor agonist |
JP7208020B2 (ja) | 2016-06-29 | 2023-01-18 | ハンミ ファーマシューティカル カンパニー リミテッド | グルカゴン誘導体、その結合体、及びそれを含む組成物、並びにその治療的用途 |
-
2013
- 2013-03-07 AR ARP130100755A patent/AR090281A1/es unknown
- 2013-03-08 JP JP2014560857A patent/JP6383667B2/ja active Active
- 2013-03-08 US US14/383,334 patent/US11168109B2/en active Active
- 2013-03-08 TW TW109115220A patent/TW202033536A/zh unknown
- 2013-03-08 RU RU2014138621A patent/RU2639256C2/ru active
- 2013-03-08 TW TW102108193A patent/TW201341395A/zh unknown
- 2013-03-08 CA CA2866473A patent/CA2866473A1/en not_active Abandoned
- 2013-03-08 SG SG11201405537UA patent/SG11201405537UA/en unknown
- 2013-03-08 EP EP13757904.1A patent/EP2822972A4/en active Pending
- 2013-03-08 CN CN201380023673.2A patent/CN104271604A/zh active Pending
- 2013-03-08 KR KR1020130025344A patent/KR101679612B1/ko active IP Right Grant
- 2013-03-08 UA UAA201410250A patent/UA114192C2/uk unknown
- 2013-03-08 CN CN201910479805.1A patent/CN110339369B/zh active Active
- 2013-03-08 WO PCT/KR2013/001885 patent/WO2013133659A1/en active Application Filing
- 2013-03-08 IN IN7956DEN2014 patent/IN2014DN07956A/en unknown
- 2013-03-08 AU AU2013228144A patent/AU2013228144B2/en not_active Ceased
- 2013-03-08 MY MYPI2014002586A patent/MY165211A/en unknown
- 2013-03-08 MX MX2014010734A patent/MX369613B/es active IP Right Grant
-
2014
- 2014-09-08 PH PH12014502004A patent/PH12014502004A1/en unknown
-
2015
- 2015-03-10 HK HK15102405.8A patent/HK1201858A1/xx unknown
-
2018
- 2018-03-13 JP JP2018044927A patent/JP2018104465A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2013228144A1 (en) | 2014-09-25 |
WO2013133659A1 (en) | 2013-09-12 |
TW201341395A (zh) | 2013-10-16 |
TW202033536A (zh) | 2020-09-16 |
EP2822972A1 (en) | 2015-01-14 |
AU2013228144B2 (en) | 2017-08-17 |
KR101679612B1 (ko) | 2016-11-25 |
RU2014138621A (ru) | 2016-04-27 |
CA2866473A1 (en) | 2013-09-12 |
UA114192C2 (uk) | 2017-05-10 |
PH12014502004A1 (en) | 2014-11-24 |
MX369613B (es) | 2019-11-14 |
EP2822972A4 (en) | 2015-12-16 |
US20150299247A1 (en) | 2015-10-22 |
AR090281A1 (es) | 2014-10-29 |
CN110339369A (zh) | 2019-10-18 |
IN2014DN07956A (ru) | 2015-05-01 |
KR20130103447A (ko) | 2013-09-23 |
JP6383667B2 (ja) | 2018-08-29 |
RU2639256C2 (ru) | 2017-12-20 |
US11168109B2 (en) | 2021-11-09 |
JP2018104465A (ja) | 2018-07-05 |
MX2014010734A (es) | 2014-12-05 |
SG11201405537UA (en) | 2014-11-27 |
JP2015514690A (ja) | 2015-05-21 |
CN110339369B (zh) | 2024-01-23 |
MY165211A (en) | 2018-03-05 |
CN104271604A (zh) | 2015-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20181696T1 (hr) | Postupak za pripremu dipeptidnih derivata lizin-glutaminske kiseline | |
HK1201858A1 (en) | An improved process for preparation of physiologically active polypeptide complex | |
HK1200466A1 (en) | Method for the preparation of surfactant peptides | |
ZA201403189B (en) | Method for preparing physiologically active polypeptide complex | |
LT2734536T (lt) | Estetrolio gamybos būdas | |
IL235802A0 (en) | A new process for the preparation of 2-cyclopentyl-6-methoxy-isonicotinic acid | |
HRP20181931T1 (hr) | Kontinuirani proces za pripravu (s)-2-acetiloksipropionske kiseline | |
HK1217717A1 (zh) | 高產率製備生理活性多肽複合物的改進方法 | |
IL236450A0 (en) | Process for the preparation of 5-fluoro-h1-pyrazoles | |
PL399418A1 (pl) | Sposób wytwarzania 4-metoksydihydrochalkonu | |
PL399419A1 (pl) | Sposób wytwarzania 4-metoksydihydrochalkonu | |
EP2780348A4 (en) | PROCESS FOR THE PRODUCTION OF TENOFOVIR | |
IL236466A0 (en) | Pharmaceutical composition for the release of active components | |
PT2817305T (pt) | Um processo melhorado para a preparação de aprepitant | |
HK1198647A1 (en) | Method for preparation of octahydrocyclopenta[c]pyrrole -[c] | |
EP2906536A4 (en) | IMPROVED METHOD FOR PRODUCING A PERINDOPRIL INTERMEDIATE PRODUCT | |
HUP1200675A2 (en) | Process for the preparation of pyrimidinyl-piperazines | |
GB201215246D0 (en) | Process for preparation of blood group antigen derivatives |